Studies showed that mass production of DNA origami even inside the cell or on a micrometer scale could be high-throughput and low-cost , , . This research has shown that bacteriophages can efficiently generate single-stranded DNA of various lengths and sequences, enabling scalable and cost-effective production. The bacteriophage-based process involves the creation of precursor DNA containing target sequences interspersed with self -excising 'cassettes', each containing two DNAzymes cleaved by Zn 2+ . While there are still some challenges in vivo production of DNA origami structures, some studies have shown that it is not impossible to achieve. A flexible method for creating precise tile-based nanostructures by folding individual long single-stranded RNAs (ssRNAs) has been devised in which each nanostructure comprises a single ssRNA molecule, and they can be cloned, expressed, and selffolded in E. coli . Hence, developing a method for in vivo or intracellular production could replace chemically synthesizing single-stranded staples or scaffolds, it might eliminate the need for purification or at least reduce the purification effort due to the potentially high production yield. Adopting a "molecular manufacturing" approach could be possible to adopt an approach like manufacturing processes. Just as workers operate within factories to manufacture products, artificial cells (as factories) could serve as suitable environments for enzymes, proteins, DNAzymes, or other functional biomolecules (as workers) to execute necessary catalytic functions on oligonucleotides, producing DNA staples and scaffolds, or even facilitating selfassembly of DNA structures within these artificial cells (Fig. ). Using artificial cells in place of biological ones could aid in removing unwanted elements and regulating processes through the manipulation and design of cells to perform desired functions. Additionally, employing CRISPR/Cas9 with encoded guide RNA may assist in trimming a lengthy DNA strand containing all target sequences of staples (Fig. ), while polymerases (Fig. ) and primases (Fig. ) may be applied to replicate longer and shorter RNA strands, respectively, and the reverse transcriptases (Fig. ) produce the DNA strands, afterward. Next, the generated strands undergo self-assembly in the subsequent stage, either within the artificial cell or in vitro. Given the practicality of this efficient and less errorprone method, the purification step will be minimized in the DNA origami fabrication procedure, helping streamline the whole process of DNA production and reducing the cost of production in terms of both time and energy. Based on recent findings, the obstacles faced in progressing DNA nanostructure-based antitumor agent delivery may be primarily related to technical hurdles, regulatory considerations, and ethical implications, rather than financial limitations. This indicates that there is potential for this approach to be a lucrative and effective therapeutic method . Authorization approval of an oligonucleotide anti-cancer therapeutic utilizing the DNA origami platform for delivery could potentially lead to a significant market boost for these therapeutic approaches.